Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Frontier Biotechnologies Inc. (China)
Homepage:
frontierbiotech.com
Alternate names:
Frontier Biotech,
Frontier Biotechnologies,
Frontier Biotechnologies Inc.
ROR:
02em6j372
OpenAlex ID:
I4405267367
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and LongIn VivoHalf-Life
2009
·
Dong Xie
, Cheng Yao
, et al.
·
Antimicrobial Agents and Chemotherapy
·
86
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
2020
·
Bin Su
, Cheng Yao
, et al.
·
Chinese Medical Journal
·
54
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
2022
·
Weijuan Shang
, Wenhao Dai
, et al.
·
Antiviral Research
·
43
PDF
Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
2016
·
Hongwei Zhang
, Ronghua Jin
, et al.
·
AIDS Research and Therapy
·
42
PDF
Development of a series of flurbiprofen and zaltoprofen platinum( iv ) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA
2022
·
Zuojie Li
, Linming Li
, et al.
·
Dalton Transactions
·
28
Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results
2016
·
Wanqiu Yang
, Qingqing Xiao
, et al.
·
Xenobiotica
·
17
Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders
2024
·
Lina Fan
, Yue Hu
, et al.
·
Frontiers in Cellular and Infection Microbiology
·
15
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study
2022
·
Bin Su
, Cheng Yao
, et al.
·
Journal of Infection
·
15
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life
2010
·
Dong Xie
, Cheng Yao
, et al.
·
Antimicrobial Agents and Chemotherapy
·
8
Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports
2025
·
Chuantiao Zhang
, Tingting Xie
, et al.
·
Retrovirology
·
6
PDF
Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
2023
·
Huiling Qin
, Cheng Yao
, et al.
·
Naunyn-Schmiedeberg s Archives of Pharmacology
·
5
PDF
Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study
2018
·
Hao Wu
, Cheng Yao
, et al.
·
SSRN Electronic Journal
·
4
Application of Fluorescent Labeling Technique in the Research of Biology and Medicine
2014
·
WU Chao-zh
·
Journal of Chongqing Institute of Technology
·
4
Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report
2025
·
Yaozu He
, Baolin Liao
, et al.
·
Virology Journal
·
2
PDF
A Biologically Optimized PEG-IFN-α2 Variant Exhibits Potent Anti-HBV and Immunomodulatory Efficacy
2026
·
Asha Ashuo
, Jianyu Ye
, et al.
·
Emerging Microbes & Infections
PDF
Long-Acting Albuvirtide Combined with Intensive Immunochemotherapy for HIV-associated Diffuse Large B-Cell Lymphoma: A Retrospective Study
2026
·
Han Zhao
, Qianyu Wang
, et al.
·
Research Square
PDF
Efficacy and safety of albuvirtide intensification for low-level viremia in people with HIV-1: A retrospective pilot study
2026
·
Chuantiao Zhang
, Shu Qian
, et al.
·
International Journal of Infectious Diseases
PDF
Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial
2026
·
Yihong Zhou
, Yuanyuan Qin
, et al.
·
BMC Infectious Diseases
FB-7013: A Novel, Long-Duration siRNA Targeting Mannan-Binding Lectin Serine Protease 2 (MASP2) Exhibits Therapeutic Potential for Treatment of IgAN
2025
·
Michael Zhiyan Wang
·
Journal of the American Society of Nephrology
FB-7011: A Novel, Long-Duration siRNA Dual-Targeting Both Complement Factor B (CFB) and Mannan-Binding Lectin Serine Protease 2 (MASP2) Exhibits Therapeutic Potential for Treatment of IgAN
2025
·
Michael Zhiyan Wang
·
Journal of the American Society of Nephrology
Preparation Microcapsules and Application Technology of Botanical Virucide Eugenol
2015
·
Zhang Xiao-ya
·
Journal of Biological Control
Application of the Staudinger Ligation in Bio-labeling
2014
·
Xu Fa
·
Journal of Chongqing Institute of Technology
The New Enemy of Sexually Transmitted Diseases-Microbicide
2012
·
Jiang He
·
Journal of Chongqing Institute of Technology
Advances in the Research of CXCR4 Antagonists as Anti-HIV Agents
2012
·
Rongjian Lu
·
Journal of Chongqing Institute of Technology
Development of the Chemical Modification of Long-acting Peptide Drugs
2012
·
Gong Meng-jia
·
Journal of Chongqing Institute of Technology
Show more works
View as search
Works count:
27
Citation count:
1,512
Year
Topic
Type